The BioVentrix Revivent TC™, the first "less invasive" system for left ventricular remodeling, has yielded positive one-year results in an online publication of the European Journal of Heart Failure. Based on a CE Mark study, the paper will be published in print in the January issue of the...
Blue Shield of CA and Blue Cross Blue Shield Federal Employee Plan to Include Itamar WatchPAT™ in Their Policiesread the full article >
Approvals / Clearance
Boston Scientific Corporation has announced the CE Mark approval of its Vercise™ Neural...read the full article >
Clinical Studies / Trials
Abbott has announced the launch of the TRILUMINATE Pivotal trial to evaluate the safety and...read the full article >
Orchestra BioMed™, Inc., tells us it has received CE Mark approval for its...read the full article >